News | January 16, 2013

Biopsy Capability Being Developed for Gamma Medica’s LumaGEM

Molecular breast imaging company Gamma Medica, Inc. is expanding the capabilities of its LumaGEM Molecular Breast Imaging (MBI) System with a biopsy accessory. Gamma Medica’s technology clearly lights up tumors, even those obscured by dense breast tissue. This new LumaGUIDE hardware and software package, currently a work-in-progress, will allow physicians to precisely identify and biopsy suspicious lesions. The new procedure is quick (about half the time of an MRI-guided biopsy), easy-to-use, and streamlined.

“Gamma Medica’s MBI-guided biopsy accessory will allow physicians to sample areas of abnormal radiotracer uptake that may be poorly visualized on other imaging modalities,” said Jim Calandra, CEO. “This new tool will allow physicians to take full advantage of MBI’s detection capabilities and enable them to guide radiological interventions including biopsy, marker placement, and surgical guidance.”
The new LumaGUIDE accessory will offer several advantages, including:

  • Depth calculation is automatically done by software: no manual calculation required. There’s a straight hub-to hub insertion of the biopsy tool.
  • The use of Tc-99m Sestamibi as a tracer allows the physician to biopsy multiple or bilateral lesions with minimal patient preparation.
  • After biopsy, samples can be scanned, providing immediate confirmation that the target lesion was accurately sampled.

“LumaGEM’s 91 percent sensitivity and 93 percent specificity allows physicians to detect cancer earlier and reduce unnecessary mastectomies, especially in the approximately 40% of women who have dense breasts, where fibrous tissue blocks the view,” said James Hugg, Ph.D., CTO. “LumaGUIDETM includes a 3rd CZT-based camera to provide precise Cartesian targeting capabilities in the x, y and z dimensions for biopsy and surgical interventions.” 

For more information:



Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...